Posted on Wednesday, October 22, 2014 at 8:23 am CDT

OTC Medications in UK by Mintel Market Sizes provides you with annual year-end market size data, most recently updated in 2014. This market covers analgesics, cough/cold/flu, gastro-intestinal, dermatological remedies and vitamins and minerals. It excludes products which require prescriptions but includes pharmacy approved. Market size comprises sales through all retail channels including direct to consumer. Market size for OTC Medications in UK is given in GBP with a minimum of five years' historical data. Market Forecast is provided for five years. Included with this snapshot is socio-economic data for UK. Population, Consumer Price Index (CPI), Gross Domestic Product (GDP), Exchange Rates.
Source: Fast Market Research
Posted on Wednesday, October 22, 2014 at 8:09 am CDT

Global Markets Direct's, 'Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014', provides an overview of the Arbor Pharmaceuticals, LLC.'s pharmaceutical research and development focus.
Source: Fast Market Research
Posted on Tuesday, October 21, 2014 at 8:43 am CDT

Global Markets Direct's, 'Cerebral Palsy - Pipeline Review, H2 2014', provides an overview of the Cerebral Palsy's therapeutic pipeline.
Source: Fast Market Research
Posted on Monday, October 20, 2014 at 8:45 am CDT

Global Markets Direct's, 'Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2014', provides an overview of the Relapsing Multiple Sclerosis (RMS)'s therapeutic pipeline.
Source: Fast Market Research
Posted on Monday, October 20, 2014 at 8:43 am CDT

Global Markets Direct's, 'Influenza B Infections - Pipeline Review, H2 2014', provides an overview of the Influenza B Infections's therapeutic pipeline.
Source: Fast Market Research
Posted on Friday, October 17, 2014 at 8:40 am CDT

Global Markets Direct's, 'Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.
Source: Fast Market Research
Posted on Friday, October 17, 2014 at 8:11 am CDT

Global Markets Direct's, 'Hyperglycemia - Pipeline Review, H2 2014', provides an overview of the Hyperglycemia's therapeutic pipeline.
Source: Fast Market Research
Posted on Friday, October 17, 2014 at 8:08 am CDT

OTC Medications in Indonesia by Mintel Market Sizes provides you with annual year-end market size data, most recently updated in 2014. This market covers analgesics, cough/cold/flu, gastro-intestinal, dermatological remedies and vitamins and minerals. It excludes products which require prescriptions but includes pharmacy approved. Market size comprises sales through all retail channels including direct to consumer. Market size for OTC Medications in Indonesia is given in IDR with a minimum of five years' historical data. Market Forecast is provided for five years. Included with this snapshot is socio-economic data for Indonesia. Population, Consumer Price Index (CPI), Gross Domestic Product (GDP), Exchange Rates.
Source: Fast Market Research
Posted on Friday, October 17, 2014 at 8:03 am CDT

Global Markets Direct's, 'Alba Therapeutics Corporation - Product Pipeline Review - 2014', provides an overview of the Alba Therapeutics Corporation's pharmaceutical research and development focus.
Source: Fast Market Research
Posted on Thursday, October 16, 2014 at 3:59 pm CDT
Glucosamine supplements are the most popular dietary additions to ease joint pain, but many consumers are confused about which form of glucosamine is the most beneficial. Numerous studies have demonstrated that glucosamine sulfate is more effective than glucosamine hydrochloride.
Source: dwgPR
Posted on Thursday, October 16, 2014 at 1:14 pm CDT
A large number of patients cannot take traditional anti-clotting drugs, such as warfarin, because of the risks of internal bleeding and drug interactions.
Source: Vascular PRN
Posted on Thursday, October 16, 2014 at 10:31 am CDT

This report provides comprehensive information on the therapeutic development for Keloids, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keloids and special features on late-stage and discontinued projects.
Source: Fast Market Research
Posted on Thursday, October 16, 2014 at 9:02 am CDT

Global Markets Direct's, 'Philogen S.p.A. - Product Pipeline Review - 2014', provides an overview of the Philogen S.p.A.'s pharmaceutical research and development focus.
Source: Fast Market Research
Posted on Thursday, October 16, 2014 at 8:46 am CDT

Global Markets Direct's, 'PharmaNova Inc. - Product Pipeline Review - 2014', provides an overview of the PharmaNova Inc.'s pharmaceutical research and development focus.
Source: Fast Market Research
Posted on Tuesday, October 14, 2014 at 8:56 am CDT

OTC Medications in Poland by Mintel Market Sizes provides you with annual year-end market size data, most recently updated in 2014. This market covers analgesics, cough/cold/flu, gastro-intestinal, dermatological remedies and vitamins and minerals. It excludes products which require prescriptions but includes pharmacy approved. Market size comprises sales through all retail channels including direct to consumer. Market size for OTC Medications in Poland is given in PLN with a minimum of five years' historical data. Market Forecast is provided for five years. Included with this snapshot is socio-economic data for Poland. Population, Consumer Price Index (CPI), Gross Domestic Product (GDP), Exchange Rates.
Source: Fast Market Research
Posted on Friday, October 10, 2014 at 2:14 pm CDT
Glucosamine and MSM (or Methylsulfonylmethane) are well-known ingredients in supplements that are believed to individually help reduce arthritis pain. However, several experts suggest that a combination of the two ingredients may be far more effective than each on their own.
Source: dwgPR
Posted on Friday, October 10, 2014 at 8:54 am CDT

Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
Source: Fast Market Research
Posted on Friday, October 10, 2014 at 8:48 am CDT

OTC Medications in Mexico by Mintel Market Sizes provides you with annual year-end market size data, most recently updated in 2014. This market covers analgesics, cough/cold/flu, gastro-intestinal, dermatological remedies and vitamins and minerals. It excludes products which require prescriptions but includes pharmacy approved. Market size comprises sales through all retail channels including direct to consumer. Market size for OTC Medications in Mexico is given in MXN with a minimum of five years' historical data. Market Forecast is provided for five years. Included with this snapshot is socio-economic data for Mexico. Population, Consumer Price Index (CPI), Gross Domestic Product (GDP), Exchange Rates.
Source: Fast Market Research
Posted on Thursday, October 09, 2014 at 11:24 am CDT

DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR’s New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai.
Source: Del Mar Pharmaceuticals Inc.
Posted on Friday, October 03, 2014 at 9:15 am CDT

Orthopedic biomaterial deals with the physical and chemical properties of the material that is implanted into the human body as constituents of devices. The material implanted is designed to perform specific biological functions by substituting or repairing the damaged tissues such as cartilage, bone, ligaments, and tendons. Bone and joint-related degenerative problems affect millions of people worldwide; this is one of the major causes for half of all chronic diseases in people aged above 50 globally. Diseases and conditions in orthopedic such as osteoporosis, arthritis, tumors, trauma, hip and knee replacement, fractures, neck problems, and soft tissue injuries are the main reasons for using temporary, permanent, or biodegradable devices. Therefore, orthopedic biomaterials play a vital role in the implantation of such devices and provide beneficial objective for physiological requirements with the complex interplay of materials properties.
Source: Fast Market Research
Posted on Thursday, October 02, 2014 at 8:31 am CDT

Global Markets Direct's, 'Acucela Inc. - Product Pipeline Review - 2014', provides an overview of the Acucela Inc.'s pharmaceutical research and development focus.
Source: Fast Market Research
Posted on Thursday, October 02, 2014 at 8:28 am CDT

Global Markets Direct's, 'Epilepsy - Pipeline Review, H2 2014', provides an overview of the Epilepsy's therapeutic pipeline.
Source: Fast Market Research
Posted on Thursday, October 02, 2014 at 8:25 am CDT

A man's failure to sustain an erection that is adequate enough for sexual activity is known as erectile dysfunction. It also refers to the inconsistency to do so, or the inability to endure it for an extended period. Erectile dysfunction can be due to a number of reasons including aging, high blood pressure, diabetes mellitus, depression, smoking, nerve or spinal cord damage, alcoholism, and low testosterone levels. Treatments for erectile dysfunction include adopting a healthy lifestyle, oral phosphodiesterase type 5 (PDE5) inhibitors, vacuum devices, and surgery. Erectile dysfunction affects the quality of life and leads to stress, anxiety, and self-confidence problems. New research is undergoing in the field of erectile dysfunction to find more enhanced and effective therapies.
Source: Fast Market Research
Posted on Thursday, October 02, 2014 at 8:24 am CDT

Global Markets Direct's, 'Diarrhea - Pipeline Review, H2 2014', provides an overview of the Diarrhea's therapeutic pipeline.
Source: Fast Market Research
Posted on Thursday, October 02, 2014 at 8:16 am CDT

Global Markets Direct's, 'Myelodysplastic Syndrome - Pipeline Review, H2 2014', provides an overview of the Myelodysplastic Syndrome's therapeutic pipeline.
Source: Fast Market Research